Vascular disruptive agent OXi4503 and antiangiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis

Preclinical research indicate that vascular disrupting agent (VDA) treatment induces extensive tumor death but also a systemic mobilization of bone marrow derived cells including endothelial progenitor cells (EPC) leading to revascularization and renewed growth within the residual tumor.